XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
RSU activity for the nine months ended September 30, 2024 was as follows:

SharesWeighted-average grant date fair value per share
Shares unvested as of December 31, 2023
5,256,833$5.63 
Granted
3,205,244$7.02 
Vested
(2,592,279)$6.36 
Forfeited
(431,446)$6.24 
Shares unvested and expected to vest as of September 30, 2024
5,438,352$6.05 
Schedule of Stock Option Activity
A summary of stock option award activity under the Company’s equity plans and related information is as follows (in thousands, except share, price and year data):
 Outstanding
stock
options
Weighted-
average
exercise
Price
Weighted-
average
remaining
contractual
life (years)
Aggregate
intrinsic
value
Balance as of December 31, 2023
9,307,142 $6.41 5.57$31,250 
Options granted— — 
Options exercised(2,135,767)2.97 
Options canceled(287,388)14.12 
Balance as of September 30, 2024
6,883,987 $7.16 5.07$15,150 
Vested and exercisable as of September 30, 2024
6,283,883 $6.46 4.89$15,017 
Vested and expected to vest
6,883,987 $7.16 5.07$15,150 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The following table summarizes the Black-Scholes option pricing model used in estimating the fair value of the stock purchase rights under the ESPP during the nine months ended September 30, 2024 and 2023. There were no ESPP offerings requiring fair value inputs during the three months ended September 30, 2024 and 2023.

Nine months ended September 30,
20242023
Expected term (in years)
0.5 - 2.0
0.5 - 2.0
Expected volatility
48% - 56%
45% - 68%
Risk-free interest rate
4.82% - 5.43%
0.10% - 5.43%
Expected dividend yield— %— %
Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount
Stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2024202320242023
Cost of revenue
$478 $653 $1,218 $1,456 
Research and development
3,097 2,865 7,455 6,786 
Sales and marketing
2,908 2,747 6,492 6,616 
General and administrative
1,955 1,693 4,330 3,812 
Total stock-based compensation expense
$8,438 $7,958 $19,495 $18,670